Clinical trials
Primary Mediastinal B Cell Lymphoma clinical trials
Below are recruiting primary mediastinal b cell lymphoma clinical trials, each written for real people, not researchers. We’re tracking 173 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05260957RecruitingPhase 2
CAR-T, mosunetuzumab, and polatuzumab for hard-to-treat lymphoma
This Phase 2 trial tests a combination approach to treat certain aggressive, relapsed, or refractory non-Hodgkin lymphomas. It may help by using CAR-T cells (a patient-specific immune treatment) along with other lymphoma medicines to shrink or control the cancer.
Miami, FloridaAges 18–80 - NCT04586478RecruitingPhase 2
CNCT19 cell therapy for relapsed or resistant non-Hodgkin lymphoma
This Phase 2 trial tests whether an injected cell therapy called CNCT19 can treat non-Hodgkin lymphoma that has come back or did not respond to prior treatment. It may help by targeting specific lymphoma cells, but you must meet several safety and medical eligibility checks.
Beijing, Beijing MunicipalityAges 18–75 - NCT06585124Recruiting
Study of t cells in lymphoma patients with HLH
This study looks at specific immune cells (T cells) in people who have a rare condition called Hemophagocytic Lymphohistiocytosis (HLH) together with an aggressive lymphoma. It aims to better understand how these cells behave, which may lead to improved diagnosis or treatment.
Rome, LazioAges 18 years+ - NCT07456371RecruitingPhase 1
PIC1 injection for relapsed or refractory B-cell lymphoma
This trial tests a new treatment called PIC1 for people with certain types of B-cell lymphoma that have come back after treatment or stopped responding. PIC1 is a type of immunotherapy that helps your immune system attack the cancer cells.
Wuhan, HubeiAges 18–75 - NCT06101381RecruitingPhase 1/Phase 2
Car-T cell therapy for relapsed or refractory leukemia and lymphoma
This trial tests whether a new immune therapy (CAR-T cells) can treat certain types of blood cancers that have come back or not responded to standard treatments. It aims to help people with aggressive B-cell lymphoma or acute lymphoblastic leukemia (ALL) that hasn't been controlled by other therapies.
Campinas, São PauloAges 3–70
Hear when a new Primary Mediastinal B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for primary mediastinal b cell lymphoma?
- Yes. Clin2 currently lists 173 recruiting primary mediastinal b cell lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a primary mediastinal b cell lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a primary mediastinal b cell lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Primary Mediastinal Large B Cell Lymphoma
- Primary Mediastinal Large B-cell Lymphoma (PMBCL)
- Refractory Primary Mediastinal Large B-Cell Lymphoma
- Recurrent Primary Mediastinal Large B-Cell Lymphoma
- Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
- T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
- Diffuse Large B Cell Lymphoma
- Mantle Cell Lymphoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.